Rhythm Pharmaceuticals raises $188.7M in public equity offering; underwriters exercise full option

RHYTHM PHARMACEUTICALS, INC.

Offering of 2,058,824 shares at $85.00 per share; underwriters exercised 30-day option for 308,823 additional shares in full.
Net proceeds expected to be approximately $188.7 million after underwriting discounts and expenses.
Proceeds to advance clinical development of product candidates and commercialization activities for IMCIVREE, plus working capital.
Company believes cash and short-term investments, including offering net proceeds, will fund operations for at least 24 months.
Underwriting agreement with Morgan Stanley and BofA Securities as representatives of the underwriters.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.